Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 8/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6099441 | 0.87 | IRAK4 (0.36) | SLC6A2SLC6A4SLC6A3CHRNA7 | |
| SCHEMBL6099436 | 0.85 | IRAK4 (0.38) | SLC6A4SLC6A3CHRNA7 | |
| SCHEMBL6100239 | 0.83 | HCRTR1 (0.37) | HCRTR1HCRTR2CHRNA7HPGDS | |
| SCHEMBL6099344 | 0.83 | TAS1R3 (0.40) | SLC6A2SLC6A4SLC6A3CHRNA7 | |
| SCHEMBL6099564 | 0.82 | CHRNA7 (0.34) | KDM1ASLC6A2SLC6A4SLC6A3CHRNA7 | |
| SCHEMBL6100564 | 0.82 | KDM1A (0.37) | KDM1ASLC6A2SLC6A4CHRNA7 | |
| SCHEMBL6098642 | 0.82 | HCRTR1 (0.37) | HCRTR1HCRTR2CHRNA7HPGDS | |
| SCHEMBL5917815 | 0.82 | CHRNA7 (0.48) | CHRNA7 | |
| Hydrochloric Acid SCHEMBL5231652 | 0.81 | CHRNA7 (0.47) | CHRNA7 | |
| SCHEMBL6100119 | 0.81 | KDM2B (0.43) | SLC6A2SLC6A4SLC6A3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-7001900-B2 | Azabicyclic compounds for the treatment of disease | PFIZER INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236270-A1 | Azabicyclic compounds for the treatment of disease | MALT1, TPMT, CYP2B6 | HCRTR1 1335/4885HCRTR2 1490/4885KDM1A 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.